LXEO insider filing: CTO reports 5,940 share grant; 64,197 owned

Rhea-AI Filing Summary

Lexeo Therapeutics (LXEO): insider transaction disclosed. The company’s Chief Technical Officer filed a Form 4 showing 5,940 shares of common stock acquired on 10/15/2025 at a price of $0. Following this, sales on 10/17/2025 totaled 2,091 shares at a weighted average price of $8.935 and 24 shares at a weighted average price of $9.561, with both ranges detailed in the notes. The filing states the sales represent shares sold to cover tax obligations on the release of RSUs.

After these transactions, the reporting person beneficially owned 64,197 shares directly, which includes 49,687 RSUs, each representing a contingent right to one share of common stock.

Insider Trade Summary

Net Seller: 2,115 shares ($18,913)

Net Sell 3 txns

Insider Otero Jose Manuel

Role Chief Technical Officer

Sold 2,115 shs ($19K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,091	$8.935	$19K
Sale	Common Stock	24	$9.561	$229.46
Grant/Award	Common Stock	5,940	$0.00	--

Holdings After Transaction: Common Stock — 64,221 shares (Direct)

Footnotes (1)

1. Represents a sale to cover tax obligations on the release of Restricted Stock Units ("RSUs"). This transaction was executed in multiple trades at prices ranging from $8.53 to $9.52. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $9.53 to $9.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Includes 49,687 RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Otero Jose Manuel

(Last) (First) (Middle)

C/O LEXEO THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, FLOOR 6

(Street)

NEW YORK NY 10010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Lexeo Therapeutics, Inc. [ LXEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technical Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/15/2025		A		5,940	A	$0	66,312	D
Common Stock	10/17/2025		S(1)		2,091	D	$8.935(2)	64,221	D
Common Stock	10/17/2025		S(1)		24	D	$9.561(3)	64,197(4)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a sale to cover tax obligations on the release of Restricted Stock Units ("RSUs").

2. This transaction was executed in multiple trades at prices ranging from $8.53 to $9.52. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. This transaction was executed in multiple trades at prices ranging from $9.53 to $9.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

4. Includes 49,687 RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.

	/s/ Youjin Choi, Attorney-in-Fact	10/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did LXEO disclose in this Form 4?

The CTO reported acquiring 5,940 shares at $0 on 10/15/2025 and selling 2,091 and 24 shares on 10/17/2025 at weighted average prices.

Why were LXEO shares sold by the reporting person?

The filing states the sales were to cover tax obligations on the release of Restricted Stock Units (RSUs).

What prices were the LXEO sales executed at?

Weighted averages of $8.935 (range $8.53–$9.52) for 2,091 shares and $9.561 (range $9.53–$9.59) for 24 shares.

How many LXEO shares does the insider now own?

Beneficial ownership after the transactions is 64,197 shares held directly, including 49,687 RSUs.

What role does the reporting person hold at LXEO?

The reporting person is the company’s Chief Technical Officer.

Are the RSUs in LXEO equivalent to common shares?

Each RSU represents a contingent right to receive one share of common stock.